Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Nvidia Options Price in $280 Billion Earnings Swing 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
California Seeks Paramount Divestitures in Warner Bros. Merger 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Tesla Raises Cybertruck Prices by $5,000 in US 
Add as a preferred source on Google
MIAMI, May 02, 2018 -- OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and financial results for the three months ended March 31, 2018 after the close of the U.S. financial markets on Tuesday, May 8, 2018.
OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 8, 2018.
Conference Call & Webcast Information
WHEN: Tuesday, May 8, 2018 at 4:30 p.m. Eastern time.
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 5976529
WEBCAST: http://investor.opko.com/events
For those unable to participate in the live conference call or webcast, a replay will be available beginning May 8, 2018 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 5976529. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for secondary hyperparathyroidism in stage 3 and 4 chronic kidney disease patients with vitamin D insufficiency (launched in November 2016), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy), OPK88002, a NK-1 antagonist to treat pruritus (itching) in dialysis patients, and OPK88001, a proprietary oligonucleotide to treat Dravet Syndrome. In addition, the Company is advancing its CTP technology, which includes a long acting hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer). OPKO also has production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.
CONTACTS
Company
OPKO Health, Inc.
David Malina, 305-575-4137
[email protected]
Director of Investor Relations
Investors
LHA Investor Relations
Miriam W. Miller, 212-838-3777
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]
